Stock GABA GABATHER AB
Add to a list
To use this feature you must be a member
Log inSign up

All News Gabather AB

Equities

GABA

SE0010869552

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-07-16 pm EDT 		5-day change 1st Jan Change
0.798 SEK -11.14% Intraday chart for Gabather AB -48.52% -43.40%
May. 30 Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 10 Gabather AB Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct A Clinical Phase II Study with GT-002 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002
AQ
Gabather AB Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct A Clinical Phase II Study with GT-002
CI
Gabather Submits Two US Patent Applications for GT-002 Use in Psychiatric Disorders
MT
Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders
AQ
Gabather AB Files Two New Patent Applications to Secure Novel Findings on the Effects of GT-002 for the Treatment of Neuropsychiatric Disorders
CI
Gabather reports initial positive results from the EEG/fMRI target engagement study
AQ
Gabather AB Reports Initial Positive Results from the EEG/fMRI Target Engagement Study
CI
Gabather AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Gabather AB receives initial EEG data analysis from the GT-002 target engagement study
AQ
Gabather AB initiates discussions with specialist doctors and researchers at Karolinska Institutet for the design of a study in individuals at risk of developing frontotemporal dementia (FTD)
AQ
Gabather AB Approaches a Significant Milestone in the Clinical Development of GT-002
CI
Gabather AB broadens the scope of EEG data analysis generated during the target engagement study by partnering with MINDIG
AQ
Gabather AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers
AQ
Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers
CI
Gabather AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Gabather, Receives Notice of Approval from the Japanese Patent Office (JPO) for its National Phase Application No. 2020-554957
AQ
Gabather AB Receives Notice of Approval from the Japanese Patent Office for National Phase Application
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GABA Stock
  4. News Gabather AB